Cargando…

Case study: biosimilar anti TNFalpha (Adalimumab) analysis of Fc effector functions

Detalles Bibliográficos
Autores principales:	Lindemann, Carsten, Mayer, Silke, Engel, Miriam, Schroeder, Petra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980296/ http://dx.doi.org/10.1186/1753-6561-7-S6-P30

Ejemplares similares

Cellular tools for biosimilar mAb analysis
por: Lindemann, Carsten, et al.
Publicado: (2013)

PReS-FINAL-2342: Anti-TNFALPHA therapy targeys PKB/C-AKT induced resistance of effector cells to suppression in juvenile arthritis
por: Wehrens, E, et al.
Publicado: (2013)

Pain experience in children with juvenile idiopathic arthritis on TNFalpha-inhibitors
por: Jeppesen, JH, et al.
Publicado: (2008)

Vector induced skewing of antibody Fc-effector functions
por: Chung, A, et al.
Publicado: (2012)

A208 REAL WORLD EVIDENCE ANALYSIS WITH ADALIMUMAB BIOSIMILAR, MSB 11022, REPORTED WITH PATIENT CARE PROGRAM
por: Cheung, S, et al.
Publicado: (2023)

T.06.4 LONG TERM EFFICACY AND SAFETY OF ABP 501 ADALIMUMAB BIOSIMILAR ON INFLAMMATORY BOWEL DIESASES: THE ADASWITCH STUDY
por: Cingolani, A., et al.
Publicado: (2022)

ELISpot analysis of lipopolysaccharide-stimulated leukocytes: human granulocytes selectively secrete IL-8, MIP-1beta and TNFalpha
por: Smedman, Christian, et al.
Publicado: (2008)

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
por: Jiang, Yijia, et al.
Publicado: (2023)

P66 Adalimumab originator versus biosimilar in children and young people with JIA
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2022)

A175 REAL-WORLD EXPERIENCE ON SWITCHING FROM ADALIMUMAB TO BIOSIMILARS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE – AN OBSERVATIONAL STUDY FROM THREE TERTIARY CARE CENTRES
por: Bedi, H, et al.
Publicado: (2023)

AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

Efficacy of adalimumab in sarcoidosis
por: Kamphuis, LSJ, et al.
Publicado: (2010)

Real‐life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab Biosimilar Patient Registry Data
por: Kapoor, Sanjiv, et al.
Publicado: (2019)

Correction to: AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

Navigating adalimumab biosimilars: an expert opinion
por: Abitbol, Vered, et al.
Publicado: (2023)

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
por: Francois, Fabien, et al.
Publicado: (2021)

Regulatory role of C5a anaphylatoxin on the Fcγ Rs effector system in immune complex-induced diseases
por: Schmidt, RE, et al.
Publicado: (2004)

Evaluation of the JIA treatment with adalimumab in ukraine
por: Ponochevna, Elena, et al.
Publicado: (2014)

Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
por: Velayudhan, Jyoti, et al.
Publicado: (2016)

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
por: Huizinga, Tom W. J., et al.
Publicado: (2020)

Focal cerebral ischemia in the TNFalpha-transgenic rat
por: Pettigrew, L Creed, et al.
Publicado: (2008)

Molecular discrimination of responders and nonresponders to anti-TNFalpha therapy in rheumatoid arthritis by etanercept
por: Koczan, Dirk, et al.
Publicado: (2008)

Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator
por: Cingolani, Linda, et al.
Publicado: (2021)

Contextualizing the Price of Biosimilar Adalimumab Based on Historical Rebates for the Original Formulation of Branded Adalimumab
por: Dickson, Sean R., et al.
Publicado: (2023)

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
por: Zhao, Sizheng, et al.
Publicado: (2018)

An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
por: Zhou, Xin, et al.
Publicado: (2021)

Consistency of Product Quality for SB5, an Adalimumab Biosimilar
por: Lee, JongAh Joanne, et al.
Publicado: (2023)

Adalimumab and severe uveitis in juvenile idiopathic arthritis (JIA) therapy
por: Alpigiani, MG, et al.
Publicado: (2008)

Effectiveness of dose reduction of etanercept and adalimumab in patients with rheumatoid arthritis
por: Martínez-Pérez, Rosalía, et al.
Publicado: (2011)

Expression and function of FcγRII on NK cells in rhesus macaques
por: He, X, et al.
Publicado: (2012)

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
por: Henry, Alistair I, et al.
Publicado: (2011)

Differential response to anakinra and adalimumab in a patient with DADA2 syndrome
por: Toz, B, et al.
Publicado: (2015)

Chimeric antigen receptors (CARs) incorporating mutations in the IgG4 Fc spacer region to eliminate Fc receptor recognition results in improved CAR T cell persistence and anti-tumor efficacy
por: Jonnalagadda, Mahesh, et al.
Publicado: (2013)

Developing a quantitative model of antibody effector function
por: Boesch, AW, et al.
Publicado: (2012)

Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
por: Joos, R, et al.
Publicado: (2011)

Quality of life in patients with juvenile arthritis: adalimumab might make a difference
por: Denisova, Rina, et al.
Publicado: (2011)

Administration of adalimumab in paediatric patients with juvenile idiopathic arthritis in South Ural region
por: Glazyrina, Galina
Publicado: (2014)

Clinical and economic efficiency to reduce dose etanercept and adalimumab in patients with rheumatoid arthritis
por: Martínez-Pérez, Rosalía, et al.
Publicado: (2012)

Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2021)

Quantitative single-cell characterization of CAR+ T cell effector functions
por: Liadi, Ivan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_52kdv0nudd2o04ejho8h7enq39